INDIA- Medical diagnostic company HORIBA, has announced its collaboration with SigTuple in order to hasten the deployment of its AI100, a solution for AI-assisted digital pathology, throughout the Indian subcontinent.
SigTuple combines the power of microfluidics, robotics, artificial intelligence (AI) and cloud computing to create smart diagnostic solutions which make quality healthcare delivery affordable and accessible.
SigTuple’s AI100 is a leading AI-assisted digital pathology system. A pathologist receives its AI-based cell classification on a cloud platform, greatly improving the pathologist’s quality and efficiency.
Additionally, telepathology and a smooth transition from manual to digital microscopy are made possible by remotely displaying the microscopic view of the slide.
The goal of SigTuple’s AI100 is to replace the manual microscope in laboratories. It presently automates the microscopic review of the two most frequent lab tests, peripheral blood smear, and urine, and there are plans to expand AI capabilities for more tests on the same platform.
“It is truly an honor for us to partner with the HORIBA India team. In a very short time, HORIBA has disrupted the market and emerged as a leader in the small-midsized lab and the high-end market – covering 10,000+ customers in the region.
“…This partnership is a strong vote of confidence on the SigTuple team’s efforts over the last 7 years and will go a long way in driving the adoption of AI powered digital cell morphology across the Indian subcontinent.
This is also one of the first, if not the first instance of a global medical device major, getting into a distribution partnership with an Indian start-up,” stated Dr.Tathagato Rai Dastidar – Founder & CEO, SigTuple.
This strategic partnership will be built on the synergies of the complementary nature of products that SigTuple would be offering to further strengthen the HORIBA product basket.
Experts claim that the peripheral blood smear review is a potent and crucial diagnostic tool that gives professionals knowledge about a range of illnesses.
These illnesses include anemia, viral and bacterial infections, hematological disorders, and several other potentially fatal medical ailments. Almost all laboratories around India currently carry out this manually.
According to the business, AI100 not only uniformizes reporting standards but also makes telepathology possible, allowing pathologists to examine cases anywhere in the world while seated in one place.
Dr Rajeev Gautam, Corporate Officer, HORIBA, Japan & President, HORIBA India, commented, “This strategic partnership will be built on the synergies of the complementary nature of products that SigTuple would be offering to further strengthen the HORIBA product basket.”
He highlighted that HORIBA is glad to optimize its market penetration and customer connection to make this partnership successful in India and global markets.
Liked this article? Sign up to receive our regular email newsletters, focused on Africa and World’s healthcare industry, directly into your inbox. SUBSCRIBE HERE
